[
  {
    "sentence": "Assuming that a somatic mutation would be present in only a subset of the cells from which we obtained DNA for analysis, we predicted that the mutant allele would be present in less than 50% of the sequencing reads arising from that genomic site (Fig. 1A and 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Assuming that a somatic mutation would be present in only a subset of the cells from which we obtained DNA for analysis, we predicted that the mutant allele would be present in less than 50% of the sequencing reads arising from that genomic site (Fig. 1A and 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Although more than 94% of the mutations observed across the genome were missense and synonymous changes, the somatic mutations observed in DNMT3A, TET2, ASXL1, and PPM1D had a strong tendency to disrupt gene protein-coding sequences by introducing a frame-shift, nonsense, or splice-site disruption (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CLONAL HEMATOPOIESIS AND SUBSEQUENT HEMATOLOGIC CANCER AND DEATH\nParticipants with clonal hematopoiesis were substantially more likely to receive a first diagnosis of hematologic cancer 6 months or more after DNA sampling (Table S6 in the Supplementary Appendix) than participants without any detectable putative somatic mutations (hazard ratio, 12.9; 95% confidence interval [CI], 5.8 to 28.7; P<0.001 by Cox proportional-hazards analysis of time to a diagnosis of hematologic cancer, with adjustment for age and sex) (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Participants with candidate drivers and those with unknown drivers had similarly elevated risks (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the 31 participants who received a diagnosis of hematologic cancer more than 6 months after DNA sampling, 13 participants (42%) had shown clonal hematopoiesis in their initial DNA sample (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Panel C shows the proportions of participants who had clonal hematopoiesis with candidate or unknown drivers among 31 participants in whom hematologic cancers were diagnosed at least 6 months after DNA sampling, as compared with the proportions in a group of age-matched persons without hematologic cancer over a similar follow-up period.Participants with clonal hematopoiesis had reduced overall survival (hazard ratio for death, 1.4; 95% CI, 1.0 to 1.8; P = 0.03 by Cox proportional-hazards model, with adjustment for age and sex) (Fig. 3D and 3E).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Participants with clonal hematopoiesis were substantially more likely to receive a first diagnosis of hematologic cancer 6 months or more after DNA sampling (Table S6 in the Supplementary Appendix) than participants without any detectable putative somatic mutations (hazard ratio, 12.9; 95% confidence interval [CI], 5.8 to 28.7; P<0.001 by Cox proportional-hazards analysis of time to a diagnosis of hematologic cancer, with adjustment for age and sex) (Fig. 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Participants with candidate drivers and those with unknown drivers had similarly elevated risks (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the 31 participants who received a diagnosis of hematologic cancer more than 6 months after DNA sampling, 13 participants (42%) had shown clonal hematopoiesis in their initial DNA sample (Fig. 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Participants with clonal hematopoiesis had reduced overall survival (hazard ratio for death, 1.4; 95% CI, 1.0 to 1.8; P = 0.03 by Cox proportional-hazards model, with adjustment for age and sex) (Fig. 3D and 3E).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Whole-genome sequencing analysis of the preclinical blood DNA sample revealed 1153 putative somatic mutations at a characteristic frequency in Participant 1 and 660 such mutations in Participant 2 (Fig. 4A and 4B), evidence that a clone had amplified from a single cell and that was consistent with the number of mutations observed in AML genomes.29 The whole-genome sequencing data showed that many known pathogenic mutations were present at the characteristic allele frequency of the clone (Fig. 4A and 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These 2 types of CEBPA mutation frequently co-occur in AML.36\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Whole-genome sequencing analysis of the preclinical blood DNA sample revealed 1153 putative somatic mutations at a characteristic frequency in Participant 1 and 660 such mutations in Participant 2 (Fig. 4A and 4B), evidence that a clone had amplified from a single cell and that was consistent with the number of mutations observed in AML genomes.29 The whole-genome sequencing data showed that many known pathogenic mutations were present at the characteristic allele frequency of the clone (Fig. 4A and 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "DISCUSSION\nWe observed clonal hematopoiesis with somatic mutations in 10% of the elderly study participants, with increasing frequency with age (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Most such clonal expansions appeared to involve driver genes and mutations that are also driver mutations in hematologic cancers (Fig. 2A and 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We found the presence of such clones to be a risk factor for subsequent hematologic cancers (hazard ratio, 12.9; 95% CI, 5.8 to 28.7) (Fig. 3A and 3B) and death (hazard ratio, 1.4; 95% CI, 1.0 to 1.8) (Fig. 3D and 3E).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Most cases of clonal hematopoiesis appeared to involve mutations in a specific subset of the genes recognized as drivers of blood cancers,22 such as DNMT3A, ASXL1, and TET2 (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Such an inference would align with data from studies involving patients with cancer and mouse models.12-14 Functional experiments have shown that loss of DNMT3A impairs differentiation of hematopoietic stem cells, resulting in an increase in the number of such cells in the bone marrow,39 and that loss of TET2 results in increased self-renewal of hematopoietic stem cells and a competitive growth advantage.40\nWe detected clonal hematopoiesis in 42% of the participants who received a diagnosis of cancer more than 6 months later (Fig. 3C), and such clones were a strong risk factor for these cancers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Fourth, initial detection of clonal hematopoiesis might justify periodic screening for the presence of cooperating mutations at low allele frequencies that could presage cancer (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We observed clonal hematopoiesis with somatic mutations in 10% of the elderly study participants, with increasing frequency with age (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Most such clonal expansions appeared to involve driver genes and mutations that are also driver mutations in hematologic cancers (Fig. 2A and 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We found the presence of such clones to be a risk factor for subsequent hematologic cancers (hazard ratio, 12.9; 95% CI, 5.8 to 28.7) (Fig. 3A and 3B) and death (hazard ratio, 1.4; 95% CI, 1.0 to 1.8) (Fig. 3D and 3E).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Most cases of clonal hematopoiesis appeared to involve mutations in a specific subset of the genes recognized as drivers of blood cancers,22 such as DNMT3A, ASXL1, and TET2 (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We detected clonal hematopoiesis in 42% of the participants who received a diagnosis of cancer more than 6 months later (Fig. 3C), and such clones were a strong risk factor for these cancers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Fourth, initial detection of clonal hematopoiesis might justify periodic screening for the presence of cooperating mutations at low allele frequencies that could presage cancer (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  }
]